Fully human antibody therapeutics for the treatment of cancer and auto-immune disorders to be pursued.
Organon, the human health care business unit of Akzo Nobel, and Medarex will work together to develop and potentially commercialize fully human antibody therapeutics for the treatment of cancer and auto-immune disorders, utilizing Medarex’s UltiMAb Human Antibody Development System® and Organon’s expertise in drug discovery and development.
Under the terms of the agreement, Medarex and Organon plan to share development and commercialization responsibilities on any antibody-based therapeutics resulting from this collaboration and to share revenues generated from the sale of such therapeutic products.
“We have recently increased our efforts in Cambridge, Massachusetts, to identify novel biologicals that will be effective treatments for auto-immune and oncological disorders, this additional collaboration with Medarex represents a further step toward becoming an effective biological drug hunting company,” says David Nicholson, executive vp, R&D, at Organon.
